Research Analysts Offer Predictions for FULC Q3 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Fulcrum Therapeutics in a note issued to investors on Tuesday, June 2nd. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.07) per share for the quarter, up from their prior forecast of ($0.27). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.65) EPS, FY2027 earnings at ($0.13) EPS and FY2028 earnings at ($0.13) EPS.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06.

A number of other research analysts have also recently issued reports on the company. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Fulcrum Therapeutics in a research report on Wednesday. Truist Financial cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research note on Tuesday. Stifel Nicolaus cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target for the company. in a research note on Tuesday. Leerink Partners cut Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price target for the company. in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of “Reduce” and an average price target of $8.20.

Fulcrum Therapeutics Stock Up 2.5%

Fulcrum Therapeutics stock opened at $3.22 on Thursday. Fulcrum Therapeutics has a 12-month low of $2.83 and a 12-month high of $15.74. The business’s 50-day moving average price is $7.08 and its two-hundred day moving average price is $9.14. The stock has a market cap of $214.55 million, a PE ratio of -2.80 and a beta of 2.93.

Institutional Trading of Fulcrum Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in FULC. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth about $30,000. Quarry LP bought a new stake in shares of Fulcrum Therapeutics during the third quarter worth about $35,000. Meeder Asset Management Inc. bought a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth about $39,000. Summit Securities Group LLC bought a new stake in shares of Fulcrum Therapeutics during the first quarter worth about $53,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors.

Key Headlines Impacting Fulcrum Therapeutics

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Negative Sentiment: Fulcrum discontinued pociredir after FDA safety concerns, effectively removing its only clinical-stage asset and sharply weakening the company’s near-term outlook. Reuters article
• Negative Sentiment: Multiple brokerages downgraded the stock, including Cantor Fitzgerald, Leerink Partners, Stifel, HC Wainwright, and JPMorgan, reflecting reduced confidence after the program shutdown.
• Negative Sentiment: Several law firms and shareholder groups announced investigations into possible securities-law violations, adding litigation risk and more uncertainty for investors. PR Newswire article
• Neutral Sentiment: The company is exploring strategic alternatives, including a potential sale or merger, which could provide a catalyst if value can be salvaged from the remaining assets. Yahoo Finance article

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.